Nebulize Lidocaine

PreclinicalSmall molecule

SSakarya University

Nebulize Lidocaine is one of 4 small molecule programs targeting Lidocaine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LidocaineNot yet recruiting

LidocainePreclinical

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Lidocaine

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Approved

1 2

Phentolamine Mesylate

NNovalar Pharmaceuticals, Inc.

Preclinical

1 3

Nebulize Lidocaine

SSakarya University

Preclinical

1 4

Lidocaine Lubricant

SSimon Fraser University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Lidocaine

NCT07267897

Clinical

Trials by Indication[1]

Lidocaine1 trial

Nebulized Lidocaine vs 3% Sodium Chloride in Pediatric Adenoid/Tonsil Surgery

Not yet recruiting·SSakarya University·N/A·NCT07267897·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nebulize Lidocaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nebulize Lidocaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nebulize Lidocaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sakarya University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSakarya University

Nebulize Lidocaine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Lidocaine1 trial

References

Drug Info

Quick Facts

Related News